Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy. Neuromuscul Disord 2006 Nov;16(11):745-8
Date
09/29/2006Pubmed ID
17005398DOI
10.1016/j.nmd.2006.07.021Scopus ID
2-s2.0-33750465212 (requires institutional sign-in at Scopus site) 19 CitationsAbstract
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option.
Author List
Cripe LH, Barber BJ, Spicer RL, Wong BL, Weidner N, Benson DW, Markham LWMESH terms used to index this publication - Major topics in bold
AdolescentCardiac Output, Low
Cardiotonic Agents
Disease Progression
Dobutamine
Dose-Response Relationship, Drug
Home Infusion Therapy
Humans
Infusions, Intravenous
Male
Milrinone
Muscular Dystrophy, Duchenne
Palliative Care
Quality of Life
Time Factors
